Compound Tested: Guanidine hydrochloride (GH) (Sigma Chemical Co), White powder, 98% pure, CAS No. 50-01-1, Synonyms: Aminomethanamidine hydrochloride, Carbamidine hydrochloride, Aminoformamidine hydrochloride, Iminourea hydrochloride Dose Prenaration: Administered in sterile water. equ~vaLen~was used to calculate the required dose
Dose Prenaration: Administered in sterile water. equ~vaLen~was used to calculate the required dose
Test and Results:
The weight of base Tests were conducted in accordance with EPA test guidelines (a,b) .
Protocol: Rats (Sprague-Dawley) or mice (ICR) were caged individually in stainless steel wire-mesh cages and fed certified Purina rodent Chow R Diet 5002. Water was available ad lib. Animals were fasted overnight before dosing. Dosing was by oral-gavage with maximum volume per gavage of 10 ml/kg body weight for rats and 6 ml/kg body weight for mice. Animals were observed for clinical signs and mortality daily for a two-week observation period. Body weights were recorded prior to dosing and once weekly during the course of the study. All animals were submitted for necropsy.
Results:
Rats: GH was found to be stable in the vehicle for 4 hr. Dosing was completed within 2 hr of preparation. Five groups of male and female rats were dosed along with a control group. The most frequently observed clinical signs were central nervous system-neuromuscular disturbance (80/86) and gastrointestinal (GI) tract symptoms (53/86). These signs appeared within 2 to 4 hr. and disappeared after 7 days. These signs exhibited a dose response relationship. The weight gains of survivors were not significantly affected by dosing. Gross necropsy revealed lesions in the digestive system (10/16 male, 11/20 females).
The mortality data are presented in Table 1 . The remaining deaths occurred on the 2nd day. The median lethal dose (MLD) was calculated by probit analysis (c). The MLD for males was 556.5 (95% confidence limit 492.3, 630.9) and for females was 474.6 (95% confidence limit 402,562.7).
Mice: Five groups of males and females were dosed along with a control group. The most frequently observed clinical signs in animals administered GH were respiratory signs (gasping 68/100) and behavioral signs (60/100). The behavioral signs included irritability, inactivity, disorientation, hyperactivity, hypotonia, jumping, tremors and twitching. Although clinical signs were observed at each dose level, there was no clear dose-response relationship of severity or duration of the symptoms. The weight gains of survivors were not affected by dosing. At necropsy, pulmonary edema was observed in 6 out 20 animals dosed at 794 mg/kg. No lesions were observed in the other animals. The mortality data is presented in Table 2 . o All deaths (42/100) occurred within 5 hr after dosing. The median lethal doses (MLD) were calculated by probit analysis(c) to be 570.8 mg/kg (95% confidence limit 491, 694) for male and 621 mg/kg (95%' confidence limit 492, 1183) for female mice.
